id: NEW:placebo_dose_extension_treatment_to_NEW:methadone_dose_requirement
name: Placebo Dose-Extension Treatment Protocol â†’ Methadone Dose Requirement
from_node:
  node_id: NEW:placebo_dose_extension_treatment
  node_name: Placebo Dose-Extension Treatment Protocol
to_node:
  node_id: NEW:methadone_dose_requirement
  node_name: Methadone Dose Requirement
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Open-label placebo administered alongside methadone creates conditioned therapeutic response'
- 'Step 2: Classical conditioning enhances perceived medication potency through learned associations'
- 'Step 3: Individuals with substance use disorder may have higher salience attribution increasing placebo
  sensitivity'
- 'Step 4: Enhanced placebo effect allows equivalent therapeutic benefit at lower methadone doses'
- 'Step 5: Reduced methadone dosage decreases risk of cardiotoxicity and respiratory complications'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Annabelle M Belcher et al. 2019. "Open-label dose-extending placebos for opioid use
    disorder: a protocol for a randomised controlled clinical trial with methadone treatment." https://doi.org/10.1136/bmjopen-2018-026604'
  supporting_citations:
  - Additional citations require full-text access - this is a protocol paper describing planned research
  - Prior placebo effect research in neuropsychiatric disorders referenced but not specifically cited
    in abstract
  - Conditioning/dose-extension methodology literature referenced but not specifically cited in abstract
  doi: 10.1136/bmjopen-2018-026604
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: This protocol describes a randomized controlled trial testing whether combining open-label
  placebos with conditioning/dose-extension methodology can enhance the effective potency of methadone
  in treatment-seeking OUD patients. The hypothesis is that placebo effects can reduce the required methadone
  dose while maintaining therapeutic efficacy, thereby reducing dose-dependent adverse effects including
  cardiotoxicity and respiratory complications.
quantitative_effects:
  sample_size: 120
moderators:
- name: salience_attribution
  direction: strengthens
  strength: moderate
  description: Individuals with substance use disorder tend to have higher salience attribution, potentially
    increasing sensitivity to placebo effects
- name: personality_factors
  direction: strengthens
  strength: weak
  description: Exploratory outcomes include personality factors associated with propensity to demonstrate
    placebo effect
- name: environmental_factors
  direction: strengthens
  strength: weak
  description: Exploratory outcomes include environmental factors associated with OUD and placebo response
structural_competency:
  equity_implications: This mechanism addresses a structural healthcare delivery challenge - the tension
    between effective OUD treatment and medication side effects. By potentially reducing required methadone
    doses through placebo augmentation, this approach could improve medication safety profiles and treatment
    retention. However, the study does not explicitly address structural barriers to OUD treatment access
    or how placebo interventions might differentially affect populations facing healthcare access disparities.
    The approach avoids individual blame by focusing on neurobiological conditioning mechanisms rather
    than patient compliance or motivation.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.769598'
  extraction_confidence: low
  prompt_version: 2.1-canonical-validated
